Swedish Orphan Biovitrum AB Owners

Health Care & Life Sciences » Pharmaceuticals | Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB | Ownership

Companies that own Swedish Orphan Biovitrum AB

Name

Shares Held

% Shares Out

Change In Shares

% of Assets

As of Date

Swedbank Robur Fonder AB

13,511,268

4.94%

-1,749,164

0.56%

06/18/2018

EdgePoint Investment Group, Inc.

13,231,360

4.84%

-295,015

2.92%

07/18/2018

Fjärde AP-fonden

10,900,308

3.99%

-752,937

1.78%

04/30/2018

AMF Fonder AB

8,175,231

2.99%

-1,011,053

1.32%

04/30/2018

SEB Investment Management AB

5,995,170

2.19%

-832,287

0.51%

04/30/2018

Lannebo Fonder AB

4,087,616

1.5%

-6,267,677

2.2%

04/30/2018

The Vanguard Group, Inc.

4,058,193

1.49%

39,314

07/31/2018

Max Mitteregger Kapitalförvaltning AB

3,542,600

1.3%

-1,107,400

29.86%

04/30/2018

Norges Bank Investment Management

2,937,128

1.08%

-952,515

0.01%

12/31/2017

AFA Sjukförsäkringsaktiebolag (Invt Mgmt)

2,843,306

1.04%

118,229

3.88%

12/31/2017

About Swedish Orphan Biovitrum AB

View Profile

Address	Tomtebodavägen 23A Solna AB 112 76 Sweden
Employees	-
Website	http://www.sobi.com
Updated	07/08/2019
Swedish Orphan Biovitrum AB engages as a biopharmaceutical company. It provides therapies and services for patients with rare diseases. The firm's core products include Kineret within the inflammation therapeutic area; and Orfadin, Ammonaps, and Ammonul within the genetics and metabolic therapeutic area.